Quick Takeaways
- MORGAN STANLEY filed SCHEDULE 13G/A for Stoke Therapeutics, Inc. Common Stock (STOK).
- Disclosed ownership: 6.5%.
- Date of event: 31 Dec 2024.
MORGAN STANLEY - 31 Dec 2024 SCHEDULE 13G/A Report for Stoke Therapeutics, Inc. Common Stock (STOK)
- Filing Manager
- MORGAN STANLEY
- Reporting Manager
- Morgan Stanley
- Symbol
- STOK
- Shares outstanding
- 52,719,062 shares
- Disclosed Ownership
- 3,426,739 shares
- Ownership
- 6.5%
- Form type
- SCHEDULE 13G/A
- Filing time
- 03 Feb 2025, 16:36:44 UTC
- Date of event
- 31 Dec 2024
- SEC
- View on sec.gov
Quoteable Key Fact
"MORGAN STANLEY disclosed 6.5% ownership in Stoke Therapeutics, Inc. Common Stock (STOK) on 31 Dec 2024."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 03 Feb 2025, 16:36.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | 6.5% | 3,426,739 | 0 | 3,426,696 | Christopher O'Hara | Authorized Signatory, Morgan Stanley | |
| Morgan Stanley Capital Services LLC | 5.4% | 2,879,280 | 0 | 2,879,280 | Christopher O'Hara | Authorized Signatory, Morgan Stanley Capital Services LLC |